Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Composite cryoablation + hyperthermia ablation with toripalimab and neoadjuvant chemotherapy in resectable stage IB–IIIB NSCLC
ChiCTR2600127431Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological complete response rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600127431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127431.